Estrella Immunopharma, Inc.
ESLA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001844417
No open-market purchases or sales by Estrella Immunopharma, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $4.99M in total; no superinvestor holds it.
Other share classesESLAW
Q2 2026 vs. Q1 2026
How the institutions holding Estrella Immunopharma, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 16 | 15 | −1 |
| Shares | 5.18M | 4.79M | −384.6K (−7.4%) |
| Value | $5.49M | $4.99M | −$503.5K (−9.2%) |
New holders (2)
Institutions that held Estrella Immunopharma, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Barclays PLC | 126 | $131 | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | $2 | 0.00% |
Sold out (3)
Institutions that held Estrella Immunopharma, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Wells Fargo & Company | 264,388 | $280.3K |
| Royal Bank of Canada | 6,600 | $7.00K |
| Morgan Stanley | 1 | $1 |